Loading...
•
Sep 30, 2021
Bridgebio Q3 2021 Earnings Report
Reported financial results for Q3 2021 and provided a business update.
Key Takeaways
BridgeBio Pharma reported its Q3 2021 financial results, highlighting the topline results from Part A of the Phase 3 ATTRibute-CM trial expected by the end of 2021, progress in the RAS cancer portfolio, advancements in the gene therapy pipeline, and the repurchase of $148.4 million in common stock. The company ended the quarter with $599.6 million in cash, cash equivalents, and marketable securities.
Topline results from Part A of the Phase 3 ATTRibute-CM trial of TTR stabilizer for ATTR-CM are expected by the end of 2021.
Meaningful progress was made in the RAS cancer portfolio with the discovery of next-generation KRAS G12C dual inhibitors and novel PI3kα:RAS breakers.
Advancements in the gene therapy pipeline included the first patient dosed in the Canavan disease trial and a newly announced program targeting classic galactosemia.
The company repurchased $148.4 million in BridgeBio common stock under the 2021 Share Repurchase Program.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...